FibroBiologics, Inc. (FBLG)

NASDAQ: FBLG · Real-Time Price · USD

0.2480

-0.0032 (-1.27%)

At close: Feb 20, 2026, 4:00 PM EST

0.2450

-0.0030 (-1.21%)

After-hours: Feb 20, 2026, 5:52 PM EST

FibroBiologics Employees

FibroBiologics had 13 employees as of December 31, 2024. The number of employees increased by 3 or 30.00% compared to the previous year.

Employees

13

Change (1Y)

3

Growth (1Y)

30.00%

Revenue / Employee

n/a

Profits / Employee

-$1,423,154

Market Cap

16.50M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2024	13	3	30.00%
Dec 31, 2023	10	3	42.86%
Sep 30, 2023	8	1	14.29%
Jun 30, 2023	7	-	-
Dec 31, 2022	7	-	-

Related Stocks

Company Name	Employees
CASI Pharmaceuticals	233
Curis	34
Citius Pharmaceuticals	23
IN8bio	17
Serina Therapeutics	13
Lexaria Bioscience	7
Intensity Therapeutics	7
Allarity Therapeutics	7

Employee Rankings

FBLG News

10 days ago - FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University - GlobeNewsWire
15 days ago - FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia - GlobeNewsWire
4 weeks ago - FibroBiologics to Present at the DealFlow Discovery Conference - GlobeNewsWire
6 weeks ago - FibroBiologics CEO Issues Letter to Shareholders - GlobeNewsWire
6 weeks ago - FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference - GlobeNewsWire
6 weeks ago - FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease - GlobeNewsWire
7 weeks ago - FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis - GlobeNewsWire
2 months ago - FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire